Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advancements research identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://friedrichd824gax2.elbloglibre.com/profile